247 related articles for article (PubMed ID: 37460463)
41. Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells.
Rausch M; Rutz A; Allard PM; Delucinge-Vivier C; Docquier M; Dormond O; Wolfender JL; Nowak-Sliwinska P
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208775
[TBL] [Abstract][Full Text] [Related]
42. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
43. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
[TBL] [Abstract][Full Text] [Related]
44. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
45. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
46. A proteogenomic analysis of clear cell renal cell carcinoma in a Chinese population.
Qu Y; Feng J; Wu X; Bai L; Xu W; Zhu L; Liu Y; Xu F; Zhang X; Yang G; Lv J; Chen X; Shi GH; Wang HK; Cao DL; Xiang H; Li L; Tan S; Gan HL; Sun MH; Qiu J; Zhang H; Zhao JY; Ye D; Ding C
Nat Commun; 2022 Apr; 13(1):2052. PubMed ID: 35440542
[TBL] [Abstract][Full Text] [Related]
47. Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways.
Selvarajah J; Nathawat K; Moumen A; Ashcroft M; Carroll VA
Cell Death Dis; 2013 Oct; 4(10):e865. PubMed ID: 24136229
[TBL] [Abstract][Full Text] [Related]
48. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
von Roemeling CA; Marlow LA; Wei JJ; Cooper SJ; Caulfield TR; Wu K; Tan WW; Tun HW; Copland JA
Clin Cancer Res; 2013 May; 19(9):2368-80. PubMed ID: 23633458
[TBL] [Abstract][Full Text] [Related]
49. Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation.
Marona P; Górka J; Kwapisz O; Jura J; Rys J; Hoffman RM; Miekus K
Cell Death Dis; 2022 Sep; 13(9):814. PubMed ID: 36138026
[TBL] [Abstract][Full Text] [Related]
50. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
51. A multigene assay identifying distinct prognostic subtypes of clear cell renal cell carcinoma with differential response to tyrosine kinase inhibition.
Choudhury Y; Wei X; Chu YH; Ng LG; Tan HS; Koh V; Thike AA; Poon E; Ng QS; Toh CK; Kanesvaran R; Tan PH; Tan MH
Eur Urol; 2015 Jan; 67(1):17-20. PubMed ID: 25018036
[TBL] [Abstract][Full Text] [Related]
52. Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma.
Sekino Y; Teishima J; Liang G; Hinata N
Int J Urol; 2022 Dec; 29(12):1419-1428. PubMed ID: 36122306
[TBL] [Abstract][Full Text] [Related]
53. Recent advances in the systemic treatment of metastatic non-clear cell renal cell carcinomas.
Ito K
Int J Urol; 2019 Sep; 26(9):868-877. PubMed ID: 31183903
[TBL] [Abstract][Full Text] [Related]
54. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma.
Clark DJ; Dhanasekaran SM; Petralia F; Pan J; Song X; Hu Y; da Veiga Leprevost F; Reva B; Lih TM; Chang HY; Ma W; Huang C; Ricketts CJ; Chen L; Krek A; Li Y; Rykunov D; Li QK; Chen LS; Ozbek U; Vasaikar S; Wu Y; Yoo S; Chowdhury S; Wyczalkowski MA; Ji J; Schnaubelt M; Kong A; Sethuraman S; Avtonomov DM; Ao M; Colaprico A; Cao S; Cho KC; Kalayci S; Ma S; Liu W; Ruggles K; Calinawan A; Gümüş ZH; Geiszler D; Kawaler E; Teo GC; Wen B; Zhang Y; Keegan S; Li K; Chen F; Edwards N; Pierorazio PM; Chen XS; Pavlovich CP; Hakimi AA; Brominski G; Hsieh JJ; Antczak A; Omelchenko T; Lubinski J; Wiznerowicz M; Linehan WM; Kinsinger CR; Thiagarajan M; Boja ES; Mesri M; Hiltke T; Robles AI; Rodriguez H; Qian J; Fenyö D; Zhang B; Ding L; Schadt E; Chinnaiyan AM; Zhang Z; Omenn GS; Cieslik M; Chan DW; Nesvizhskii AI; Wang P; Zhang H;
Cell; 2019 Oct; 179(4):964-983.e31. PubMed ID: 31675502
[TBL] [Abstract][Full Text] [Related]
55. Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan.
Ito K; Mikami S; Tatsugami K; Masumori N; Shinohara N; Kondo T; Nakanishi S; Nagashima Y; Eto M; Kamba T; Kuroda N; Tomita Y; Matsuyama H; Onishi T; Tsushima T; Nakazawa H; Oya M; Ozono S; Naito S; Asano T
Clin Genitourin Cancer; 2018 Dec; 16(6):e1201-e1214. PubMed ID: 30224330
[TBL] [Abstract][Full Text] [Related]
56. [Pilot Study on MicroRNAs as Biomarkers of Response to Sunitinib Treatment in Patients with Metastatic Renall Cell Carcinoma].
Kováčová J; Juráček J; Poprach A; Büchler T; Kopecký J; Fiala O; Svoboda M; Lojová M; Slabý O
Klin Onkol; 2018; 31(Supplementum1):161-162. PubMed ID: 29808694
[TBL] [Abstract][Full Text] [Related]
57. Cancer-associated fibroblasts in renal cell carcinoma: implication in prognosis and resistance to anti-angiogenic therapy.
Ambrosetti D; Coutts M; Paoli C; Durand M; Borchiellini D; Montemagno C; Rastoin O; Borderie A; Grepin R; Rioux-Leclercq N; Bernhard JC; Pagès G; Dufies M
BJU Int; 2022 Jan; 129(1):80-92. PubMed ID: 34107167
[TBL] [Abstract][Full Text] [Related]
58. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
59. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
60. Special issue "The advance of solid tumor research in China": Multi-omics analysis based on 1311 clear cell renal cell carcinoma samples identifies a glycolysis signature associated with prognosis and treatment response.
Tian X; Wang Y; Xu W; Tang H; Zhu S; Anwaier A; Liu W; Wang W; Zhu W; Su J; Qu Y; Zhang H; Ye D
Int J Cancer; 2023 Jan; 152(1):66-78. PubMed ID: 35579992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
